A Phase 1-2 Study of a Farnesyltransferase Inhibitor, Tipifarnib, Combined With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Samankaltaisia teoksia

• Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
  Tekijä: Garcia-Manero, Guillermo, et al.
  Julkaistu: (2012)
• A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
  Tekijä: Faderl, Stefan, et al.
  Julkaistu: (2008)
• Final Report of Phase II Study of Sorafenib, Cytarabine, and Idarubicin for Initial Therapy in Younger Patients with Acute Myeloid Leukemia
  Tekijä: Ravandi, Farhad, et al.
  Julkaistu: (2014)
• Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
  Tekijä: Ravandi, Farhad, et al.
  Julkaistu: (2019)
• Clofarabine, Idarubicin, and Cytarabine (CIA) as Frontline Therapy for Patients ≤60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)
  Tekijä: Nazha, Aziz, et al.
  Julkaistu: (2013)